Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA

Andrew J. Lees, Joaquim Ferreira, Olivier Rascol, Heinz Reichmann, Fabrizio Stocchi, Eduardo Tolosa, Werner Poewe

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Opicapone is a third generation, highly potent and effective catechol O‑methyltransferase (COMT) inhibitor that optimizes the pharmacokinetics and bioavailability of L-DOPA therapy. Areas covered: In this review, the authors describe the preclinical and clinical development of opicapone. In PD patients with motor fluctuations, once daily opicapone administration was well-tolerated and consistently reduced OFF-time and increased ON-time without increasing the frequency of troublesome dyskinesia, and these benefits were maintained over at least a year of continued open-label therapy. Expert commentary: With its convenient once-daily regimen, adjunct opicapone should be considered as an effective option for use in L-DOPA treated PD patients experiencing motor fluctuations.

Original languageEnglish
Pages (from-to)649-659
Number of pages11
JournalExpert Review of Neurotherapeutics
Volume17
Issue number7
DOIs
Publication statusPublished - Jul 3 2017

Keywords

  • COMT inhibition
  • L-DOPA
  • motor fluctuations
  • Opicapone
  • Parkinson’s disease
  • wearing-off

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA'. Together they form a unique fingerprint.

Cite this